• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Upexi Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    1/28/26 5:01:29 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email
    upxi_8k.htm
    0001775194false--06-3000017751942026-01-222026-01-22iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ________________________

     

    FORM 8-K

    ________________________

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 22, 2026

    _______________________________

     

    UPEXI, INC.

    (Exact name of registrant as specified in its charter)

    _______________________________

     

    Delaware

     

    001-40535

     

    83-3378978

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    3030 N. Rocky Point Drive, Suite 420

    Tampa, FL 33607

    (Address of Principal Executive Offices) (Zip Code)

     

    (727) 287-2800

    (Registrant's telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

    _______________________________

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.00001

     

    UPXI

     

    NASDAQ

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

     

     

     

    Item 5.03. Amendments to Articles of Incorporation or Bylaws.; Change in Fiscal Year.

     

    As previously disclosed, at the June 16, 2025 special meeting of the shareholders of Upexi, Inc. (the “Company”), the shareholders approved the increase (the “Amendment”) of the number of authorized shares of the Company’s capital stock to 1,010,000,000 shares, consisting of (i) 1,000,000,000 shares of common stock, par value $0.00001 per share (the “Common Stock”), and (ii) 10,000,000 shares of blank check preferred stock, par value $0.00001 per share (the “Preferred Stock”). On January 22, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Certificate of Amendment”), which amended and restated Article V of the Company’s Certificate of Incorporation to increase the Company’s authorized capital stock to 1,010,000,000 shares, consisting of (i) 1,000,000,000 shares of Common Stock, and (ii) 10,000,000 shares of Preferred Stock.

     

    The Certificate of Amendment was approved and adopted by the Company’s board of directors and stockholders in accordance with Section 242 of the Delaware General Corporation Law.

     

    A copy of the Certificate of Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 9.01              Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.

     

    Exhibit Description

    3.1

     

    Certificate of Amendment to the Certificate of Incorporation

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL Document)

     

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    UPEXI, INC.

     

     

     

     

     

    Dated: January 28, 2026

     

    /s/ Andrew J. Norstrud

     

     

     

    Name: Andrew J. Norstrud

     

     

     

    Title: Chief Financial Officer

     

     

     

    3

     

    Get the next $UPXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    8/4/2025$15.00Buy
    Alliance Global Partners
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Marshall Allan bought $90,000 worth of shares (50,000 units at $1.80), increasing direct ownership by 1% to 4,046,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/23/25 7:53:48 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan was granted 1,600,000 shares and bought $310,500 worth of shares (150,000 units at $2.07), increasing direct ownership by 78% to 3,996,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/17/25 6:43:21 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Salkind Gene bought $127,500 worth of shares (50,000 units at $2.55) (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    11/21/25 6:32:50 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upexi to Host Second Quarter 2026 Earnings Call on February 10th at 5:30 p.m. ET

    TAMPA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the second quarter 2026 ended December 31, 2025, on Tuesday, February 10, 2026. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi Second Quarter 2026 Earnings CallDate:Tuesday, February 10, 2026Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar For

    1/29/26 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Announces Pricing of $36 Million Private Placement of Convertible Note Priced Above the Market

    Transaction to Increase Solana Treasury by 12% to over 2.4 million SOL Offering is Accretive to Adjusted Solana per Share upon Conversion TAMPA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it has entered into a securities purchase agreement with Hivemind Capital Partners for the purchase of a Convertible Note in exchange for locked Solana with an aggregate original principal amount of approximately $36 million (the "Note"). The Note is collateralized by the SOL used as consideration to purchase the Note. It has an interest rate of 1.0% payable on a quarterly basi

    1/13/26 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Participate in Upcoming January Investor Conferences

    TAMPA, Fla., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that management will participate in the following January 2026 investor conferences. Details for each conference can be found below. The link to webcasted presentations can be found on our Investor Relations website here: https://ir.upexi.com/news-events/ir-calendar. 12th Annual Alpha North Capital Event ConferenceDate: January 16-18, 2026Location: Grand Hyatt Baha Mar, Nassau, BahamasAttendees: Brian Rudick, Chief Strategy OfficerType: Investor Meetings Sidoti Micro-Cap Virtual ConferenceDa

    1/9/26 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Upexi, Inc. with a new price target

    Alliance Global Partners initiated coverage of Upexi, Inc. with a rating of Buy and set a new price target of $15.00

    8/4/25 8:09:26 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

    6/16/25 7:42:40 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    SEC Filings

    View All

    Upexi Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    1/30/26 5:05:40 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    1/28/26 5:01:29 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    1/14/26 5:28:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Marshall Allan bought $90,000 worth of shares (50,000 units at $1.80), increasing direct ownership by 1% to 4,046,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/23/25 7:53:48 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan was granted 1,600,000 shares and bought $310,500 worth of shares (150,000 units at $2.07), increasing direct ownership by 78% to 3,996,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/17/25 6:43:21 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Salkind Gene bought $127,500 worth of shares (50,000 units at $2.55) (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    11/21/25 6:32:50 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    5/31/23 7:05:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:37:37 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Leadership Updates

    Live Leadership Updates

    View All

    Upexi Welcomes Jon Najarian to the Upexi Advisory Committee

    TAMPA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced the addition of Jon Najarian (Twitter: @jonnajarian) to the Upexi Advisory Committee, joining Arthur Hayes and S◎L Big Brain as founding Upexi Advisory Committee members. Jon Najarian is a highly influential figure in the world of finance, renowned for his deep expertise in options trading and market strategy. A former professional football player, Jon co-founded options trading firm Mercury Trading and later launched financial education company Marke

    10/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Financials

    Live finance-specific insights

    View All

    Upexi to Host Second Quarter 2026 Earnings Call on February 10th at 5:30 p.m. ET

    TAMPA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the second quarter 2026 ended December 31, 2025, on Tuesday, February 10, 2026. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi Second Quarter 2026 Earnings CallDate:Tuesday, February 10, 2026Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar For

    1/29/26 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026

    Digital Asset Revenue was Approximately $6.1 Million for the Quarter Gross Profit Totaled $8.3 Million, up 183% Year-Over-Year Net Income Increased to $66.7 Million, Compared to a Net Loss of $1.6 Million, Year-over-Year Conference Call Scheduled for today, November 11, 2025, at 5:30 p.m. Eastern Time TAMPA, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced record digital asset revenue for the fiscal first quarter ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025 Total revenue for the quarter was $9.2 mill

    11/11/25 5:25:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Host First Quarter 2026 Earnings Call on November 11th at 5:30 p.m. ET

    TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the first quarter 2026 ended September 30, 2025, on Tuesday, November 11, 2025. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi First Quarter 2026 Earnings CallDate:Tuesday, November 11, 2025Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar Fo

    11/6/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care